Therapeutic options in peripheral T cell lymphoma

Table 1 Clinical trial efficacy results of novel single-agent treatments

Agent	Targeting site	Phase	No. of evaluable patients	Type of patients	Outcomes	ClinicalTrial.gov ID	References
Tipifarnib	Farnesyltransferase inhibitor	II	12	PTCL	50 % ORR	NCT00082888	[49]
Darinaparsin	Organic arsenic compound	II	7	PTCL	28.6 % ORR, 3.6 months median TTF, 6.4 months OS	NCT00421213	[50]
Panobinostat	Pan-deacetylase inhibitor	II	139	CTCL	17.3 % ORR	NCT00425555	[51]
Denileukin diftitox	Interleukin fusion protein	III	263	CTCL	38 % ORR, median DoR was 277 days	NCT00050999	[52]
Denileukin diftitox	Interleukin fusion protein	III	263	CTCL	38 % ORR, median DoR was 277 days	NCT00051012	[52]
Ixazomib	Proteasome inhibitor	I	4	PTCL	1 PR	NCT00893464	[53]
Sorafenib	Multikinase inhibitor	—	12	PTCL/CTCL	42 % ORR, 4 CR, 1 PR	—	[54]
Forodesine	PNP inhibitor	II	101	CTCL	No CR, 11 % PR, 50 % SD, median DoR was 191 days	NCT00501735	[55]

ORR overall response rate, CR complete response, PR partial response, SD stable disease, TTF time to treatment failure, OS overall survival, DoR duration of response, PNP purine nucleoside phosphorylase

ISSN: 1756-8722